

PRESCRIPTION PROFILE OF ABIRATERONE IN METASTATIC PROSTATE CARCINOMA

V. Escudero-Vilaplana, A. Ribed Sánchez, E. González Haba, M.N. Sánchez Fresneda, S. Buendía Bravo, A. Ais Larisgoitia, I. Marquínez Alonso, X. García González, M. Sanjurjo Sáez
Hospital General Universitario Gregorio Marañón, Pharmacy Department, Madrid, Spain.

BACKGROUND AND OBJECTIVE

In September 2011, the European Medicines Agency (EMA) approved the use of **abiraterone** for metastatic castration resistant prostate cancer in men whose disease had progressed on a docetaxel-based chemotherapy. In March 2012, abiraterone was included for this indication in our formulary's hospital.

- **Main objective** was to assess the prescription profile of abiraterone for metastatic prostate cancer in a tertiary hospital.
- **Secondary objective** was to analyzed whether patients' characteristic were consistent with the criteria for use of abiraterone in our center.

METHODS

- ✓ **Design:** A retrospective, observational study was carried out in all patients treated with abiraterone for metastatic prostate cancer in our center.
- ✓ **Study period:** March 2012 - September 2013.
- ✓ **Recorded variables:** age, performance status (ECOG), diagnosis date, type of metastasis, doses of abiraterone and beginning date, prior chemotherapy, prostate-specific antigen (PSA) at the starting abiraterone.

RESULTS

35 patients were treated with 1000 mg/24h of abiraterone during the study period.

PHYSICAL CHARACTERISTICS

Age (median [p25,p75])	77.8 (70.7, 82.0) years old	
Performance status (% patients)	ECOG= 0-1	60.0 %
	ECOG≥ 2	22.9%
	Unknown	17.1%

Median time since cancer diagnosis was 5.6 (3.1, 8.3) years

Types of metastases:

- ✓ 100% bone metastases, and also:
- ✓ 44.1% nodal lymph
- ✓ 11.8% nodal lymph and lung
- ✓ 5.9% nodal lymph and liver
- ✓ 2.9% lung
- ✓ 2.9% liver
- ✓ 2.9% liver, nodal lymph and lung

- 100% of patients received hormonal treatment and all received docetaxel after progression to chemical castration (14.3% of them received docetaxel + curtisen).
- Median time of treatment with docetaxel was 7.0 (5.0, 8.6) months.
- After progression on docetaxel, 20% were treated with cabazitaxel before starting abiraterone.
- Median PSA at initiation of treatment with abiraterone was 68.9 (22.9,197.5) mcg/l.

CONCLUSIONS

- ✓ All patients had at least bone metastases and the disease had progressed on hormone treatment and docetaxel.
- ✓ Abiraterone prescription was consistent with the use criteria in our hospital in all cases.